title: Impressive regression of primary liver cancer after treatment with sirolimus.
authors.forename: Magnus
authors.initials: M
authors.lastname: Rizell
authors.forename: Christian
authors.initials: C
authors.lastname: Cahlin
authors.forename: Styrbjörn
authors.initials: S
authors.lastname: Friman
authors.forename: Lo
authors.initials: L
authors.lastname: Hafström
authors.forename: Lars
authors.initials: L
authors.lastname: Lönn
authors.forename: Michael
authors.initials: M
authors.lastname: Olausson
authors.forename: Per
authors.initials: P
authors.lastname: Lindner
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009365:Neoplasm Regression, Spontaneous / Q000276:immunology / Q000473:pathology; D020123:Sirolimus / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D020123:Sirolimus